尿酸降低疗法与心律失常的风险降低有关:系统性审查和元分析
Palapun Waitayangkoon1, Thiratest Leesutipornchai2, Witina Techasatian2
1Department of Medicine, MetroWest Medical Center, Tufts University School of Medicine, Framingham, MA, USA.
Journal of rheumatic diseases
|April 1, 2024
概括
尿酸降低疗法 (ULT) 显著降低了心律失常的整体风险. 然而,ULT在此元分析中没有显示出心房动风险的显著降低.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尿酸降低疗法 (ULT) 在主要心血管事件预防中以其心脏保护作用而闻名.
- 对ULT对发生心律失常的风险的影响在很大程度上仍未被描述.
研究的目的:
- 调查尿酸降低疗法 (ULT) 与患心律不整的风险之间的关联.
主要方法:
- 在MEDLINE和Embase进行了系统的文献搜索,直到2023年5月.
- 包括的研究是随机对照试验和队列研究,比较ULT用户与非用户中的心律失常风险.
主要成果:
- 在五项研究中对12,420名患者的分析显示,ULT使用者整体心律不整的风险显著降低 (合并RR0.82,95%CI0.74-0.92).
- 小组分析表明,ULT使用者中心房动风险没有显著降低 (合并RR0.76,95%CI0.54-1.05).
结论:
- 尿酸降低疗法与整体心律失常的风险降低有关.
- 需要进一步的研究来验证这些发现,并探索特定的心律失常亚型.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Disturbances in Heart Rhythm
950
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
950
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Decreased pulse rate
541
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
541
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K


